Grass Pollen Allergy - Pipeline Review, H2 2011

Global Markets Direct, November 2011, Pages: 43

Grass Pollen Allergy - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Grass Pollen Allergy - Pipeline Review, H2 2011', provides an overview of the Grass Pollen Allergy therapeutic pipeline. This report provides information on the therapeutic development for Grass Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy. 'Grass Pollen Allergy - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Grass Pollen Allergy.
- A review of the Grass Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Grass Pollen Allergy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Grass Pollen Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Grass Pollen Allergy Therapeutic Products under Development, Key Players in Grass Pollen Allergy Therapeutics, Grass Pollen Allergy Pipeline Overview, Grass Pollen Allergy Pipeline, Grass Pollen Allergy Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Grass Pollen Allergy Overview
Therapeutics Development
An Overview of Pipeline Products for Grass Pollen Allergy
Grass Pollen Allergy Therapeutics under Development by Companies
Grass Pollen Allergy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Grass Pollen Allergy Therapeutics - Products under Development by Companies
Grass Pollen Allergy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Grass Pollen Allergy Therapeutics Development
Merck & Co., Inc.
Allergy Therapeutics plc
Stallergenes S.A.
Circassia Holdings Ltd.
Biomay AG
Grass Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Sublingual MPL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-7243 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ToleroMune Grass Allergy T-cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phleum Pratense - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oralair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epicutaneous Allergen Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Grass Pollen Allergen B-Cell Peptide Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Grass Allergen Model RNA Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Grass Allergen Hypoallergenic Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Grass Allergen Specific IgG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Grass Pollen Allergy Therapeutics – Drug Profile Updates
Grass Pollen Allergy - Featured News
May 24, 2011: Paladin Labs Files New Drug Submission For Oralair
May 18, 2011: Stallergenes Obtains Marketing Authorization For Oralair In Australia
Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
Sep 01, 2007: On Jan. 9, 2007, Stallergenes and Paladin Labs sign a partnership for Oralair in Canada.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Grass Pollen Allergy, H2 2011
Products under Development for Grass Pollen Allergy – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Merck & Co., Inc., H2 2011
Allergy Therapeutics plc, H2 2011
Stallergenes S.A., H2 2011
Circassia Holdings Ltd., H2 2011
Biomay AG, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Grass Pollen Allergy Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Grass Pollen Allergy, H2 2011
Products under Development for Grass Pollen Allergy – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Pollen Allergy - Pipeline Review, H2 2012
• Allergies - Pipeline Review, H2 2012
• Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012
• Rhino-Conjunctivitis - Pipeline Review, H2 2012
• Peanut Allergy - Pipeline Review, H2 2012
• Conjunctivitis - Pipeline Review, H2 2012
• Allergic Conjunctivitis - Pipeline Review, H2 2012
• Allergic Rhinitis - Pipeline Review, H2 2012
• Allergic Rhinitis - Pipeline Review, H2 2011
• Acute Pain - Pipeline Review, H2 2012